By Marc Dresner, Senior Editor, IBC Life Sciences
While antibody therapies today are most commonly associated with oncology and inflammatory diseases, the next big breakthroughs may be on the neurology front.
Dr. Trudi Veldman, Senior Director of Biologics Generation at AbbVie Bioresearch Center, says deploying bispecifics as a “Trojan Horse” to enhance transport across the blood brain barrier could finally satisfy some extreme unmet needs.
“I see a lot of opportunities around neurological diseases, such as Alzheimer’s, Multiple Sclerosis and Parkinson’s disease,” said Veldman.
In this podcast interview for Inside Antibody Engineering, Dr. Veldman explains:
• Why she thinks antibody applications in neurology look so promising
• Where she sees impressive progress elsewhere in the field
• Why Fc receptor biology needs more attention and more!
Listen to the podcast or download a transcript here!
Editor’s note: Dr. Trudi Veldman will be chairing the Antibody Therapeutics for Non-Cancer Indications track at the Antibody Engineering and Therapeutics Conference taking place December 7-10 in San Diego.
Click here for an agenda.
Or for more information visit: www.ibclifesciences.com/antibodyeng
Marc Dresner is sr. editor and special communication project lead with IBC Life Sciences. He is the former executive editor of Pharma Market Research Report, a publication for market research professionals specializing in pharmaceuticals and life sciences. He may be reached at email@example.com. Follow him @mdrezz.
Share this article with your social network, just click below to share now!